

Deep Learning-Based Detection of Xylazine Exposure from Wound Imaging

Pranav Sompalle¹; Abeed Sarker² PhD FAMIA; Jennifer Love³ MD MSCR; Jeffrey Moon⁴ MD; Anthony Spadaro⁵ MD MPH; Rachel Wightman⁶ MD FASAM; Jeanmarie Perrone⁴ MD FASAM

Introduction

Xylazine is a veterinary sedative that has emerged as a **common adulterant** of illicitly-manufactured fentanyl.

Xylazine contributes to **ulcer development** and **other health effects**.

Xylazine-associated ulcers may progress to **severe tissue necrosis** and are **managed differently** from alternative wounds.

Clinical detection of xylazine exposure is difficult:

- Xylazine testing is rarely available
- Discrimination of xylazine-associated ulcers from alternative wounds is difficult.

Accurate prediction of xylazine exposure from wound imaging can serve to:

- Identify potential xylazine exposure in a patient presenting with skin ulcers
- Guide wound management strategies specific to the cause of ulcer/wound.

Objectives

Assess whether **deep learning-based methods** can be employed for **automatic classification of xylazine wound images**.


Results

Model	All Images			Xylazine-Associated Wound Images	Negative Control Images
	Accuracy	Weighted-Average F1 Score	Macro-Average F1 Score	F1 Score	F1 Score
DenseNet121	0.97	0.96	0.73	0.47	0.98
ResNet	0.95	0.95	0.67	0.36	0.97
EfficientNetB0	0.98	0.98	0.88	0.76	0.99
SENet154	0.94	0.94	0.70	0.43	0.97

(McNemar's non-parametric significance test/z parametric significance test)

Table 1 Performance of trained models on test cohort according to accuracy and F1 scores.

Methods



Conclusions

All models learned **features unique to xylazine-associated ulcers** and exhibit **high specificity**.

High variance in intra-class and macro-averaged **F1 scores** distinguish models.

EfficientNetB0 was the **most promising model**.

Deep learning in the evaluation of **wound imaging** may enable **accurate detection of xylazine exposure**, which can then enable the following:

- specific wound care treatment**, including **antibiotic usage guidance**.
- targeted substance use disorder-related care**.
- geographic tracking** of emergence of wound complications in regions where xylazine's presence is lower.

Limitations

All models exhibit **low sensitivity**.

Images were determined to be xylazine-associated ulcers or not from **provided descriptions** and may **not represent the full spectrum of presentations**.


References

Spadaro, A., O'Connor, K., Lakamana, S., Sarker, A., Wightman, R., Love, J. S., & Perrone, J. (2023). Self-reported xylazine experiences: A mixed-methods study of Reddit subscribers. *Journal of Addiction Medicine*, 17(6), 691–694. <https://doi.org/10.1097/ADM.0000000000001216>

Dowton, A., Doernberg, M., Heiman, E., Barelli, P., Golden, M., Wang, H., Leventhal, J., Morford, K. L., & Sue, K. L. (2023). Recognition and treatment of wounds in persons using xylazine: A case report from New Haven, Connecticut. *Journal of Addiction Medicine*, 17(6), 739–741. <https://doi.org/10.1097/ADM.0000000000001198>

Perrone, J., Haroz, R., D'Orazio, J., Gianotti, G., Love, J., Salzman, M., Lowenstein, M., Thakrar, A., Klipp, S., Rae, L., Reed, M. K., Sisco, E., Wightman, R., & Nelson, L. S. (2024). National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing patients exposed to xylazine-adulterated opioids in emergency, hospital and addiction care settings. *Annals of Emergency Medicine*, 84(1), 20–28. <https://doi.org/10.1016/j.annemergmed.2024.01.041>

Oota, S. R., Rowtula, V., Mohammed, S., Liu, M., & Gupta, M. (2023). WSNet: Towards an effective method for wound image segmentation. In *2023 IEEE/CVF Winter Conference on Applications of Computer Vision (WACV)* (pp. 3233–3242). IEEE. <https://doi.org/10.1109/WACV56688.2023.00325>



¹School of Arts and Sciences at University of Pennsylvania, Philadelphia, PA; ²Emory University School of Medicine, Atlanta, GA; ³Icahn School of Medicine at Mt. Sinai, New York, NY; ⁴Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA; ⁵Rutgers New Jersey Medical School, Newark, NJ; ⁶Alpert Medical School at Brown University, Providence, RI; The authors have no disclosures relevant to this work.